Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2016-05-23
Last Posted Date
2016-10-26
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
20
Registration Number
NCT02780622

Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-05-20
Last Posted Date
2017-08-24
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
16
Registration Number
NCT02779348
Locations
🇵🇹

Human Pharmacology Unit (UFH),, S. Mamede do Coronado, Portugal

This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

First Posted Date
2016-05-13
Last Posted Date
2017-09-25
Lead Sponsor
AbbVie
Target Recruit Count
21
Registration Number
NCT02772601
Locations
🇩🇪

Boehringer Ingelheim Investigational Site, Berlin, Germany

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

First Posted Date
2016-04-28
Last Posted Date
2022-05-09
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
321182
Registration Number
NCT02754154

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

First Posted Date
2016-04-20
Last Posted Date
2023-10-03
Lead Sponsor
Alliance Foundation Trials, LLC.
Target Recruit Count
811
Registration Number
NCT02744092
Locations
🇺🇸

Washington Hospital, Fremont, California, United States

🇺🇸

Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States

🇺🇸

Saint Joseph's Medical Center, Stockton, California, United States

and more 145 locations

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

First Posted Date
2016-04-15
Last Posted Date
2023-06-09
Lead Sponsor
pharmaand GmbH
Target Recruit Count
17
Registration Number
NCT02740712
Locations
🇵🇱

BioVirtus Research Site, Kajetany, Mokra 7, Poland

🇵🇱

Zachodniopomorskie Centrum Onkologii Centrum Innowacji, Szczecin, Poland

🇵🇱

Med Polonia, Poznan, Poland

Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.

Not Applicable
Conditions
Interventions
First Posted Date
2016-03-10
Last Posted Date
2018-10-10
Lead Sponsor
Hospital do Servidor Publico Estadual
Target Recruit Count
84
Registration Number
NCT02704598
Locations
🇧🇷

Hospital do Servidor Público Estadual de São Paulo, São Paulo, SP, Brazil

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

First Posted Date
2016-01-06
Last Posted Date
2016-08-22
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
14
Registration Number
NCT02647086
Locations
🇺🇸

Regeneron Study Site, Raleigh, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath